Printed name

Date

David L. Fox

January 31, 2006

TAP6 Rec'd PCT/PTO 31 JAN 2006

Under the Paper of Reduction of 1995, no personal transmittal FORM		U.S. Patent and Tradema	PTO/SB/21 (09-04) yed for use through 07/31/2006. OMB 0651-0031 ark Office; U.S. DEPARTMENT OF COMMERCE ation unless it displays a valid OMB control number. 10/550,137 March 23, 2004 Mats Inganas
(to be used for all correspondence after initial filing) Total Number of Pages in This Submission		Examiner Name Attorney Docket Number	N/A Not Yet Assigned HO-P02773US1
EN	CLOSURES	(Check all that app	ly)
Fee Transmittal Form Fee Attached Licensing-rel Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request X Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		onvert to a Application orney, Revocation orrespondence Address sclaimer Refund	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter X Other Enclosure(s) (please Identify below): Return Receipt Postcard
Fire Name		ANT, ATTORNEY, OF	RAGENT
Firm Name FULBRIGHT & JAW Signature	ORSKI L.L.P.		7
signature / /			

40,612



Docket No.: HO-P02773US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mats Inganas et al.

Application No.: 10/550,137

Filed: March 23, 2004

Art Unit: N/A

For: PRELOADED MICROFLUIDIC DEVICES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an

Application No.: 10/550,137 Docket No.: HO-P02773US1

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02773US1.

Dated: January 31, 2006

Respectfully submitted,

David L. Fox

Registration No.: 40,612

FULBRIGHT & JAWORSKI L.L.P.

Fulbright Tower

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Attorney for Applicant

JAN 3 1 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwolk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/550,137 INFORMATION DISCLOSURE March 23, 2004 Filing Date STATEMENT BY APPLICANT First Named Inventor Mats Inganas N/A Art Unit (use as many sheets as necessary) Not Yet Assigned **Examiner Name** Attorney Docket Number_ HO-P02773US1 _ _ Sheet _ . . 1 _ _ . . 3 _ .

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-2002-0125135	09-12-2002	GYROS	
	A2	US-2003-0029724	02-13-2003	GYROS	
	А3	US-2003-0053934	03-20-2003	GYROS	
	A4	US-2003-0054563	03-20-2003	GYROS	
	A5	US-2003-0129360	07-10-2003	GYROS	
	A6	US-2003-0143114	07-31-2003	GYROS	
	A7	US-2003-0156763	08-21-2003	GYROS	
	A8	US-2003-0173650	09-18-2003	GYROS	
	A9	US-2003-0211012	11-13-2003	GYROS	
	A10	US-2004-0058408	03-25-2004	GYROS	
	A11	US-2004-0096867	05-20-2004	GYROS	
	A12	US-2004-0099310	05-27-2004	GYROS	
	A13	US-2004-0120856	06-24-2004	GYROS	
	A14	US-2004-0202579	10-14-2004	GYROS	
	A15	US-2005-0019819	01-27-2005	GYROS	
	A16	US-2005-0042770	02-24-2005	GYROS	
	A17	US-2005-0141344	06-30-2005	GYROS ·	
	A18	US-2005-0153431	07-14-2005	GYROS	
	A19	US-2005-0153432	07-14-2005	GYROS	
	A20	US-2005-0153433	07-14-2005	GYROS	
	A21	US-2005-0153434	07-14-2005	GYROS	
	A22	US-2005-0179901	08-18-2005	GYROS	
	A23	US-2005-0186685	08-25-2005	GYROS	
	A24	US-2005-0202471	09-15-2005	GYROS	
	A25	US-2005-0214442	09-29-2005	GYROS	
	A26	US-2005-0277195	12-15-2005	GYROS	
	A27	US-2005-0279925	12-22-2005	GYROS	
	A28	US-4,175,073	11-20-1979	Pharmacia Fine Chemicals AB	
	A29	US-4,563,304	01-07-1986	Pharmacia Fine Chemicals AB	
	A30	US-5,354,654	10-11-1994	Ligler et al.	
	A31	US-5,691,152	11-25-1997	E.R. Squibb & Sons, Inc.	
	A32	US-5,726,026	03-10-1998	Trustees of the University of Pennsylvania	
	A33	US-5,807,997	09-15-1998	Batista	
	A34	US-5,928,880	07-27-1999	Trustees of the University of Pennsylvania	
	A35	US-5,998,155	12-07-1999	E.R. Squibb & Sons, Inc.	
	A36	US-6,322,682	01-08-1998	GYROS	
	A37	US-6,479,299	11-12-2002	Caliper Technologies Corp.	
	A38	US-6,506,609	01-14-2003	Caliper Technologies Corp.	
	A39	US-6,632,656	10-14-2003	GYROS	
	A40	US-6,653,625	11-25-2003	GYROS	
	A41	US-6,717,136	04-06-2004	GYROS	
	A42	US-6,812,456	11-02-2004	GYROS	
	A43	US-6,812,457	01-29-2004	GYROS	

Examiner	Date	
Signature	Considered	

Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known		
	Application Number	10/550,137		
INFORMATION DISCLOSURE	Filing Date	March 23, 2004		
STATEMENT BY APPLICANT	First Named Inventor	Mats Inganas		
•	Art Unit	N/A		
(use as many sheets as necessary)	Examiner Name	Not Yet Assigned		
Sheet	Attorney Docket Number	HO-P02773US1		

A	44	US-6,852,851	02-08-2005	GYROS	
Α	45	US-6,884,395	04-26-2005	GYROS	
Α	46	US-6,919,058	07-19-2005	GYROS	
Α	47	US-6,955,738	10-18-2005	GYROS	,
Α	48	US-6,967,101	11-22-2005	GYROS	
Α	49	US-6,985,672	01-10-2006	Kylberg et al.	
Α	50	US-6,990,290	01-24-2006	GYROS	

			FOREIGN PATE	NT DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
	B1	WO-98/07019	02-19-1998	Gamera Bioscience Corporation		
	B2	WO-98/53311	11-26-1998	Gamera Bioscience Corporation		
	В3	WO-99/58245	11-18-1999	Amersham Pharmacia Biotech AB		
	B4	WO-00/25921	05-11-2000	GYROS		
	B5	WO-00/40750	07-13-2000	GYROS		
	B6	WO-00/62042	10-19-2000	GYROS		
	B7	WO-00/69560	11-23-2000	Gamera Bioscience Corporation		
	B8	WO-00/78455	12-28-2000	Tecan Trading AG		
۲	В9	WO-00/79285	12-28-2000	Gamera Bioscience Corporation		L.
	B10	WO-01/02737	01-11-2001	GYROS		
	B11	WO-01/30500	05-03-2001	GYROS		
	B12	WO-01/87486	11-22-2001	Tecan Boston		
	B13	WO-01/87487	11-22-2001	Tecan Boston		
	B14	WO-02/75312	09-26-2002	Gyros AB		
	B15	WO-04/83108	09-30-2004	GYROS		
	B16	WO-04/83109	09-30-2004	GYROS		
	B17	WO-04/103890	12-02-2004	GYROS		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	International Preliminary Report on Patentability for PCT/SE2004/000440 filed March 23, 2004.		
	C2	International Search Report for PCT/SE2004/000440 filed March 23, 2004.		
	C3	Arakawa et al., "Factors affecting short-term and long-term stabilities of proteins," Adv. Drug Deliv. Rev., 46(1-3): 307-26, 2001.		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date	
Signature	Considered	
0.5010000		

Application No. (if known): 10/550,137	Attorney Docket No.: HO-P02773US1
Certificate of Express Maili	ng Under 37 CFR 1.10
	*
I hereby certify that this correspondence is being dep Express Mail, Airbill No. EV 678180920 US in an env	posited with the United States Postal Service as velope addressed to:
MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
on <u>January 31, 2006</u> Date	
Julie Eouo	m
Signature	
Julie Erwir Typed or printed name of pers	·
	(713) 651-5187
Registration Number, if applicable	Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (3 pages) Information Disclosure Statement (2 pages) Transmittal (1 page)